Alzheimer’s disease (AD) is often described as an eraser of the mind that gradually wipes away familiar faces, beautiful scenery, and cherished memories. Rather than forgetting, we prefer to believe that people with AD are “trapped in time”.

The harsh reality is that, on average, every three seconds, someone in the world slips into this “memory desert”. Today, as the global population ages at an accelerating pace, central nervous system (CNS) diseases, particularly AD, have become one of the major threats to global health.

However, in the pharmaceutical industry, this field is widely recognized as a “research and development (R&D) black hole”. The extremely high R&D failure rate and the formidable challenge of penetrating the blood-brain barrier have made ita “Bermuda Triangle” where countless pharmaceutical companies have faltered. Yet, where there is risk, there is opportunity. CNS diseases have become the most promising “trillion-dollar blue ocean” in the pharmaceutical industry today.

While many are still watching from the sidelines, a pharmaceutical company from China has already begun sprinting ahead in this arena.

Why are Neurodegenerative Diseases Considered an “R&D black hole”?

Whether it is AD, Parkinson’s disease (PD), Huntington’s disease, or amyotrophic lateral sclerosis (ALS), they are all neurodegenerative diseases characterized by the gradual loss of neuronal structure or function. In today’s medical world, most of these diseases remain irreversible.

This irreversibility stems from the extraordinary precision and fragility of the human brain as the body’s central command system. In such an extremely complex and closed “precision system”, variables and risks increase exponentially with each step of any attempt at reversal.

The brain’s natural blood-brain barrier (BBB) acts like a firewall, blocking 98%¹ of small molecule drugs. The complexity of disease mechanisms makes drug development similar to searching for a key in a maze without a map—when the key may not even exist. As a result, the success rate of CNS drug development only stands at 6.2%², far below the industry average, while the failure rate of AD drug development is as high as 99.6%³.

AR1001: A “Reverse” BD Targeting Differentiated Breakthroughs

In the field of AD, AR1001 is regarded as one of the most promising drug candidates.

As a potential best-in-class oral medication, AR1001 has demonstrated strong convenience and a favorable safety profile in clinical studies.

Unlike traditional drugs, AR1001 is a highly selective PDE5 inhibitor. By inhibiting the PDE5 enzyme, it increases the cGMP levels in the brain, thereby demonstrating multiple neuroprotective effects. It not only promotes synaptic plasticity of neurons and enhances memory formation, but also improves cerebral blood flow and reduces neuroinflammation.

On 13 May, Fosun Pharma signed an agreement with AriBio, a South Korean company, securing an exclusive global option for AR1001 for USD60 million. Upon exercise of the option, Fosun Pharma will pay up to USD180 million in upfront and regulatory milestone payments.

AR1001 has now entered global multicenter Phase III clinical trials. This move signals that Fosun is not merely developing a drug, but securing “preferential global rights” that could revolutionizetheAD treatment landscape.

In fact, in the face of significant uncertainty, Fosun’s internal scientific committee also experienced a period of cautious hesitation. However, based on continuous monitoring and rigorous analysis of global clinical data, Fosun Pharma made a firm commitment to this strategic direction.

 “We hope everyone can live happily, healthily, and prosperously to the age of 121. AD may be the greatest challenge we face in the future. Our team deeply recognizes this, and that is why we have come together and started working toward our shared success.” (Guo Guangchang, Chairman of Fosun International, gave a quote at the AR1001 signing)

Developing a “Fosun Solution” Covering the Entire Disease Course

The introduction of AR1001 not only fills a gap in treatment but also expands Fosun’s comprehensive portfolio in neurodegenerative diseases.

In the field of AD, Fosun Pharma has established a dual-pipeline strategy for oral medications. On the one hand, AR1001 has entered global multicenter Phase III clinical trials; on the other hand, post-marketing confirmatory clinical trials for sodium oligomannate capsules are actively underway. This multi-target, multi-stage approach significantly deepens Fosun Pharma’s presence in AD while enhancing future commercialization flexibility.

In addition, in PD, Fosun Pharma has introduced the innovative drug opicapone capsules for the treatment of primary PD. Leveraging the “Early and Pilot Implementation” policy in Boao Lecheng, Hainan, it has accelerated the local adoption of global innovations, enabling domestic patients to access world-leading treatment options in step with global advances.

At the same time, Fosun is building a high-tech medical device portfolio that complements and synergizes with its innovative drugs. For patients with severe tremor impairing basic functions such as lifting a cup, Fosun-Insightec’s Magnetic Resonance-guided Focused Ultrasound (MRgFUS) enables sub-millimeter precise intervention without the need for craniotomy. With a treatment time of approximately two hours, patients experience significant improvement in tremor symptoms after treatment, regaining stable and controlled use of their hands.

While medications focus on slowing disease progression in its early stages, medical devices enable precise intervention. This multi-dimensional product portfolio is helping patients at different stages reclaim dignity in life.

Strategic Positioning: Securing a Foothold Amid Uncertainty

In Fosun Pharma’s innovation landscape, neurodegenerative diseases stand alongside oncology, and immunology and inflammation as three core R&D areas. This is not a blind bet, but a strategic choice grounded in scientific research and assessment and business thinking.

According to the China Alzheimer Report 2025, the number of AD patients in China has reached nearly 17 million. As life expectancy increases, this figure is likely to grow further. The significant unmet clinical need gives the CNS field an inherently high growth ceiling and a sustained window of opportunity.

In terms of technology innovation, neurodegenerative diseases are approaching a historic turning point in breaking this “barrier”. The approval of antibody drugs worldwide over the past two years has not only validated past scientific hypotheses, but also broken decades of R&D stagnation, creating strategic possibilities for diverse modalities, including small molecules and small nucleic acids.

The deeper business logic lies in the differences in the competitive landscape. Unlike oncology, where targets are crowded and competition is highly intense, AD has yet to see significant product overlap. This relatively uncongested competitive landscape unlocks ample strategic opportunities to build an integrated portfolio across diagnostics, therapeutics, devices, and rehabilitation.

For Fosun, this is a long-term strategic direction for the next 10 to 20 years. To this end, Fosun Pharma is not only advancing cutting-edge technologies internally, but also forging deep collaborations with leading institutions such as Huashan Hospital.

Fosun believes that realizing commercial value is essentially an extension of social value. This also reflects Fosun’s long-standing commitment to the principles of “prioritizing patient benefit above all else” and “being driven by unmet clinical needs”.

Guo Guangchang stated, “I always remind my team that everything we do should be driven by unmet clinical needs.” (Guo Guangchang’s quote at the Original Innovation Conference)

Global Commercialization: From “Borrowing a Boat to Go Out on the Ocean” to “Building a Boat to Go Out on the Ocean”

R&D innovation is the first half of the journey, while global commercialization is the true “final 100 meters”.

Guo Guangchang once said that Fosun places great emphasis on building globalization capabilities as part of its innovation efforts.

Drawing onyears of globalization capability building, Fosun has established a local team with independent commercialization capabilities and deep integration into major medical Group Purchasing Organizations (GPOs) and distribution networks across the U.S. In Europe, Fosun has achieved local manufacturing of high-end formulations. In Africa, it has built a direct sales network covering more than 40 countries.

However, the real challenge is whether it can establish a home base for a Chinese company in core markets such as Europe, the U.S., and Japan.

In China’s pharmaceutical industry, the mainstream model remains that Chinese pharmaceutical companies license the overseas rights to their products to multinational corporations (MNCs), with the latter leading global clinical trials and commercialization. However, this collaboration between Fosun Pharma and AriBio takes the opposite approach. Fosun Pharma has chosen to proactively take on commercialization in major global markets, becoming the party that “acquires the rights”.

This marks a new stage in Fosun Pharma’s globalization strategy: from deeply cultivating emerging markets such as Africa and Southeast Asia, to now making a strategic entry into core markets such as Europe, the U.S., and Japan.

As Chen Qiyu, Co-CEO of Fosun International, stated, when financial capabilities are no longer a bottleneck, the real challenge lies in whether a global commercialization system can be built. Securing the rights to AR1001, a potential best-in-class drug, in major global markets reflects Fosun Pharma’s efforts to close the global commercialization gap among Chinese pharmaceutical companies and the beginning of its deeper participation in the profit distribution of the global pharmaceutical value chain.

Challenging the “eraser of human memory” is not only about addressing unmet clinical needs but also about helping people reclaim their dignity.

As Guo Guangchang said, “Everything we do (in pharmaceutical innovation) must center on patients’ unmet needs. The epitaph of American physician Edward Livingston Trudeau reads ‘To cure sometimes, to relieve often, to comfort always’. I always hope that more diseases will become curable, with the proportion of curable cases continuing to rise and the path to cure becoming less painful.” (Guo Guangchang’s quote at the first Original Innovation Conference)

1Data source:William M. Pardridge, The Blood-Brain Barrier (2005)

2Data source:BIO Industry Analysis /Nature Biotechnology(2014)

3Data source:Jeffrey Cummings, Alzheimer’s Res & Ther (2014)